Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash from Operations (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Cash from Operations readings, the most recent being 839000.0 for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 61.55% to 839000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 4739000.0, a 50.64% increase, with the full-year FY2025 number at 4739000.0, up 50.64% from a year prior.
  • Cash from Operations hit 839000.0 in Q4 2025 for Arcadia Biosciences, down from 300000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 300000.0 in Q3 2025 to a low of 8268000.0 in Q3 2021.
  • Median Cash from Operations over the past 5 years was 3287500.0 (2022), compared with a mean of 3475350.0.
  • Biggest five-year swings in Cash from Operations: plummeted 74.49% in 2023 and later skyrocketed 82.88% in 2025.
  • Arcadia Biosciences' Cash from Operations stood at 6660000.0 in 2021, then soared by 64.28% to 2379000.0 in 2022, then tumbled by 74.49% to 4151000.0 in 2023, then skyrocketed by 47.43% to 2182000.0 in 2024, then soared by 61.55% to 839000.0 in 2025.
  • The last three reported values for Cash from Operations were 839000.0 (Q4 2025), 300000.0 (Q3 2025), and 2012000.0 (Q2 2025) per Business Quant data.